Last reviewed · How we verify

Chloroquine and sulphadoxine-pyrimethamine

Menzies School of Health Research · Phase 1 active Small molecule

Chloroquine and sulphadoxine-pyrimethamine is a Small molecule drug developed by Menzies School of Health Research. It is currently in Phase 1 development.

At a glance

Generic nameChloroquine and sulphadoxine-pyrimethamine
SponsorMenzies School of Health Research
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Chloroquine and sulphadoxine-pyrimethamine

What is Chloroquine and sulphadoxine-pyrimethamine?

Chloroquine and sulphadoxine-pyrimethamine is a Small molecule drug developed by Menzies School of Health Research.

Who makes Chloroquine and sulphadoxine-pyrimethamine?

Chloroquine and sulphadoxine-pyrimethamine is developed by Menzies School of Health Research (see full Menzies School of Health Research pipeline at /company/menzies-school-of-health-research).

What development phase is Chloroquine and sulphadoxine-pyrimethamine in?

Chloroquine and sulphadoxine-pyrimethamine is in Phase 1.

Related